8-K: Rallybio Sells ENPP1 Program to Recursion for Up to $25 Million, Extends Cash Runway

Rallybio Corporation has sold its interest in the REV102 ENPP1 inhibitor program to Recursion Pharmaceuticals for up to $25 million, including an upfront equity payment, significantly extending Rallybio's cash runway into mid-2027.

Summary

• Rallybio Corporation entered into a Membership Interest Purchase Agreement with Recursion Pharmaceuticals, Inc. and its indirect wholly-owned subsidiary, Exscientia Ventures I, Inc.
• Rallybio sold its 50% membership interest in RE Ventures I, LLC (the ENPP1 JV), which developed the REV102 program for hypophosphatasia (HPP), to Recursion's subsidiary.
• As a result of the sale, the ENPP1 JV became an indirect wholly-owned subsidiary of Recursion.
• Rallybio received an upfront payment of 1,457,952 shares of Recursion Class A Common Stock, valued at $7,500,000, based on a per share price of $5.1442.
• The Purchase Agreement includes a true-up mechanism for the upfront shares: if net proceeds from their sale are less than $7.5 million, Recursion pays the difference; if they exceed, Rallybio pays the excess.
• Rallybio is eligible for additional contingent consideration of $12,500,000 in Recursion shares upon the initiation of additional preclinical studies for the ENPP1 JV compound, with a similar true-up mechanism.
• A $5,000,000 milestone payment is due upon the initiation of dosing in a Phase 1 clinical study for the ENPP1 JV compound.
• Rallybio is also eligible to receive low single-digit royalties on annual net sales of certain products developed by the ENPP1 JV.
• The total potential consideration for Rallybio from this transaction is up to $25 million.
• This transaction is expected to extend Rallybio's cash runway into mid-2027.

Sentiment

Score: 7

Explanation: The transaction provides Rallybio with an extended cash runway and allows for a sharpened strategic focus on its lead programs, which are positive developments. While divesting an asset, the potential for future milestone payments and royalties mitigates some of the loss of future upside. The deal appears strategically sound for Rallybio.

Positives

• Extended cash runway into mid-2027 due to the upfront equity payment, providing financial stability.
• Potential to receive up to an additional $17.5 million in contingent payments and low single-digit royalties, offering future financial upside.
• Allows Rallybio to sharpen its strategic focus on advancing its core pipeline assets, RLYB116 and RLYB332, by divesting a preclinical program.
• Ensures continued development of REV102 by Recursion, potentially benefiting patients with HPP by accelerating the program.

Negatives

• Divestiture of a preclinical asset (REV102) means Rallybio will not directly benefit from its full future value beyond the agreed-upon contingent payments and royalties.
• Contingent payments are subject to the achievement of specific development and clinical milestones, which are not guaranteed.

Risks

• The contingent equity payment of $12.5 million and the $5 million milestone payment are dependent on the achievement of specific development and clinical milestones for the ENPP1 JV compound, which may not occur.
• The actual net proceeds from the sale of Recursion shares (both initial and contingent) may differ from the target values ($7.5 million and $12.5 million) due to stock price fluctuations, requiring cash adjustments between the parties.
• Rallybio's ability to successfully conduct the RLYB116 PK/PD confirmatory study and obtain results on expected timelines is subject to inherent risks in clinical development.
• The extension of Rallybio's cash runway into mid-2027 is an expectation and depends on various factors, including future operating expenses and capital expenditure requirements.
• Rallybio's ability to raise additional capital or enter into strategic partnerships for its remaining pipeline assets is uncertain.
• Competition from other biotechnology and pharmaceutical companies could impact the future prospects of Rallybio's remaining pipeline and the market for HPP treatments.

Future Outlook

Rallybio expects its cash runway to extend into mid-2027, allowing it to sharpen its focus on strategically advancing its pipeline, including the RLYB116 confirmatory PK/PD study, with topline data anticipated this year. Recursion Pharmaceuticals gains full ownership of the REV102 program, intending to accelerate its development as the first potential oral disease-modifying treatment for HPP patients.

Management Comments

• "By combining Rallybio's expertise in HPP preclinical and translational research with Recursion's integrated AI/experimental platform, we transformed this concept into the first potential oral disease-modifying treatment for HPP." Stephen Uden, M.D., Chief Executive Officer of Rallybio.
• "We look forward to the advancement of REV102 through key milestones and, ultimately, to the delivery of this important treatment to patients in need." Stephen Uden, M.D., Chief Executive Officer of Rallybio.
• "For Rallybio, divesting this preclinical asset enables us to extend our cash runway while sharpening our focus on strategically advancing our pipeline in ways that leverage our drug development expertise." Stephen Uden, M.D., Chief Executive Officer of Rallybio.
• "We eagerly anticipate the release of topline data from our ongoing RLYB116 confirmatory PK/PD study this year." Stephen Uden, M.D., Chief Executive Officer of Rallybio.
• "We extend our sincere thanks to Rallybio for their invaluable partnership in advancing this program to its current stage." David Hallett, Chief Scientific Officer of Recursion.
• "Having full ownership of this important program allows Recursion to accelerate the development of the first potential oral disease-modifying treatment to HPP patients, who currently face significant challenges with limited access to existing therapies." David Hallett, Chief Scientific Officer of Recursion.

Industry Context

The biotechnology industry frequently sees strategic asset divestitures, particularly for preclinical programs, to optimize portfolios, extend financial runways, and focus on core competencies. This transaction highlights the growing trend of leveraging AI/experimental platforms, as employed by Recursion, to accelerate drug discovery and development, especially for rare diseases like hypophosphatasia where significant unmet medical needs exist. Such deals allow companies to manage risk and allocate resources more efficiently across their pipelines.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or financial results to assess the transaction against global benchmarks.
• The structure of upfront equity, contingent milestones, and low single-digit royalties is a common industry practice for early-stage asset divestitures, reflecting a shared risk and reward model between the seller and buyer in the biotechnology sector.

Stakeholder Impact

• Shareholders: Benefit from extended cash runway, reduced burn rate, and a clearer strategic focus on core assets, potentially leading to more efficient capital allocation and reduced dilution risk in the near term.
• Patients (Hypophosphatasia): The REV102 program is expected to be accelerated under Recursion's full ownership, potentially bringing a new oral disease-modifying treatment to patients faster.

Next Steps

• Rallybio expects to file its Quarterly Report on Form 10-Q for the quarter ending September 30, 2025, which will incorporate the Purchase Agreement by reference.
• Rallybio anticipates the release of topline data from its ongoing RLYB116 confirmatory PK/PD study this year.
• Recursion Pharmaceuticals will accelerate the development of the REV102 program, including initiation of additional preclinical studies and potentially a Phase 1 clinical study.

Key Dates

Recommendation

Keywords

Rallybio, Recursion Pharmaceuticals, REV102, ENPP1 inhibitor, Hypophosphatasia, HPP, Asset Sale, Biotechnology, Rare Diseases, Cash Runway, Strategic Focus, RLYB116, RLYB332, Preclinical Development, Milestone Payments, Royalties